Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patients

Journal of Immunotherapy

Volumn 38, Issue 1, 2015, Pages 24-36

  Szmania, Susann ^a   Lapteva, Natalia ^c   Garg, Tarun ^a   Greenway, Amy ^a   Lingo, Joshuah ^a   Nair, Bijay ^a   Stone, Katie ^a   Woods, Emily ^a   Khan, Junaid ^a   Stivers, Justin ^a   Panozzo, Susan ^a   Campana, Dario ^d   Bellamy, William T ^b   Robbins, Molly ^b   Epstein, Joshua ^a   Yaccoby, Shmuel ^a   Waheed, Sarah ^a   Gee, Adrian ^c,e   Cottler Fox, Michele ^b   Rooney, Cliona ^c,e   Barlogie, Bart ^a   Van Rhee, Frits ^a   more..

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^c TEXAS CHILDREN S HOSPITAL   (United States)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Immunotherapy; Multiple myeloma; Natural killer cells

Indexed keywords

BORTEZOMIB; CD94 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR6; CYCLOPHOSPHAMIDE; DEXAMETHASONE; FLUDARABINE; INTERLEUKIN 2; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ADULT; AGED; ARTICLE; CELL COUNT; CELL CYCLE ARREST; CELL EXPANSION; CELL PROLIFERATION; CELL SURFACE; CELL THERAPY; CELL VIABILITY; CHIMERA; CLINICAL ARTICLE; CONTROLLED STUDY; CRYOPRESERVATION; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPHENOTYPING; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; INFECTIOUS COMPLICATION; LEUKOCYTE; METAPHASE; MIDDLE AGED; MULTIPLE MYELOMA; NATURAL KILLER CELL; NATURAL KILLER CELL THERAPY; REGULATORY T LYMPHOCYTE; THROMBOCYTE COUNT; TREATMENT RESPONSE; ADOPTIVE IMMUNOTHERAPY; CLINICAL TRIAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; MALE; PROCEDURES; RISK FACTOR; TRANSPLANTATION; TUMOR RECURRENCE; WESTERN BLOTTING;

AGED; BLOTTING, WESTERN; CELL PROLIFERATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY, ADOPTIVE; KILLER CELLS, NATURAL; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM RECURRENCE, LOCAL; RISK FACTORS;

EID: 84917708726     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0000000000000059     Document Type: Article

References (47)

1. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364:1046-1060.
2. Shaughnessy JD Jr, Zhan F, Burington BE, et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood. 2007;109:2276-2284.
3. Nair B, van Rhee F, Shaughnessy JD Jr, et al. Superior results of Total Therapy 3 (2003-33) in gene expression profilingdefined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance. Blood. 2010;115: 4168-4173.
4. Caligiuri MA. Human natural killer cells. Blood. 2008;112: 461-469.
5. Carbone E, Neri P, Mesuraca M, et al. HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. Blood. 2005;105: 251-258.
6. Garg TK, Szmania SM, Khan JA, et al. Highly activated and expanded natural killer cells for multiple myeloma immunotherapy. Haematologica. 2012;97:1348-1356.
7. Alici E, Sutlu T, Bjorkstrand B, et al. Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components. Blood. 2008;111:3155-3162.
8. Fujisaki H, Kakuda H, Shimasaki N, et al. Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res. 2009;69:4010-4017.
9. Berg M, Lundqvist A, McCoy P Jr, et al. Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells. Cytotherapy. 2009;11:341-355.
10. Carlens S, Gilljam M, Chambers BJ, et al. A new method for in vitro expansion of cytotoxic human CD3-CD56+ natural killer cells. Hum Immunol. 2001;62:1092-1098.
11. Shah N, Martin-Antonio B, Yang H, et al. Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity. PLoS One. 2013;8:e76781.
12. Imai C, Iwamoto S, Campana D. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood. 2005;106: 376-383.
13. Lapteva N, Durett AG, Sun J, et al. Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications. Cytotherapy. 2012;14:1131-1143.
14. Tolar J, Curtsinger J, McElmurry R, et al. Optimal xenogeneic adoptive transfer of human NK cells: fresh NK cells and IL-15 administration are superior to frozen NK cells and IL2. Blood. 2012;120:346, ASH Annual Meeting Abstracts.
15. Shi J, Tricot GJ, Garg TK, et al. Bortezomib down-regulates the cell-surface expression of HLA class I and enhances natural killer cell-mediated lysis of myeloma. Blood. 2008;111: 1309-1317.
16. Lundqvist A, Abrams SI, Schrump DS, et al. Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity. Cancer Res. 2006;66: 7317-7325.
17. Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol. 1998;102:1115-1123.
18. Lapteva N, Szmania S, van Rhee F, et al. Clinical Grade Purification and Expansion of Natural Killer Cells. Volume 19. In: Talmadge J, Whiteside T, eds. Crit Rev Oncog. Danbury, Connecticut: Begell House Inc.; 2014:121-132.
19. Lundqvist A, Yokoyama H, Smith A, et al. Bortezomib treatment and regulatory T-cell depletion enhance the antitumor effects of adoptively infused NK cells. Blood. 2009;113:6120-6127.
20. Hallett WH, Ames E, Motarjemi M, et al. Sensitization of tumor cells to NK cell-mediated killing by proteasome inhibition. J Immunol. 2008;180:163-170.
21. Shaughnessy JD Jr, Qu P, Usmani S, et al. Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3. Blood. 2011;118:3512-3524.
22. Ljunggren HG, Karre K. In search of the "missing self": MHC molecules and NK cell recognition. Immunol Today. 1990;11: 237-244.
23. Kim S, Poursine-Laurent J, Truscott SM, et al. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature. 2005;436:709-713.
24. Madueno JA, Munoz E, Blazquez V, et al. The CD26 antigen is coupled to protein tyrosine phosphorylation and implicated in CD16-mediated lysis in natural killer cells. Scand J Immunol. 1993;37:425-429.
25. Ahmadzadeh M, Rosenberg SA. IL-2 administration increases CD4+CD25hi Foxp3+ regulatory T cells in cancer patients. Blood. 2006;107:2409-2414.
26. Wahl SM, Wen J, Moutsolpoulos NM. The kiss of death: interrupted by NK-cell close encounters of another kind. Trends Immunol. 2006;27:161-164.
27. Cook G, Campbell JD, Carr CE, et al. Transforming growth factor beta from multiple myeloma cells inhibits proliferation and IL-2 responsiveness in T lymphocytes. J Leukoc Biol. 1999; 66:981-988.
28. Gasteiger G, Hemmers S, Firth MA, et al. IL-2-dependent tuning of NK cell sensitivity for target cells is controlled by regulatory T cells. J Exp Med. 2013;210:1167-1178.
29. Ghiringhelli F, Ménard C, Terme M, et al. CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-b-dependent manner. J Exp Med. 2005;202:1075-1085.
30. Trzonkowski P, Szmit E, Mysliwska J, et al. CD4+CD25+ T regulatory cells inhibit cytotoxic activity of T CD8+ and NK lymphocytes in the direct cell-to-cell interaction. Clin Immunol. 2004;112:258-267.
31. Castriconi R, Cantoni C, Della Chiesa M, et al. Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: consequences for the NK-mediated killing of dendritic cells. Proc Natl Acad Sci USA. 2003;100:4120-4125.
32. Lee JC, Lee KM, Kim DW, et al. Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J Immunol. 2004;172: 7335-7340.
33. Trotta R, Dal Col J, Yu J, et al. TGF-beta utilizes SMAD3 to inhibit CD16-mediated IFN-gamma production and antibodydependent cellular cytotoxicity in human NK cells. J Immunol. 2008;181:3784-3792.
34. Roodman GD. Mechanisms of bone metastasis. N Engl JMed. 2004;350:1655-1664.
35. Fujisaki H, Kakuda H, Imai C, et al. Replicative potential of human natural killer cells. Br J Haematol. 2009;145:606-613.
36. Barkholt L, Alici E, Conrad R, et al. Safety analysis of ex vivoexpanded NK and NK-like T cells administered to cancer patients: a phase I clinical study. Immunotherapy. 2009;1: 753-764.
37. Smith A, Khuu H, Betters DM, et al. Adoptive transfer of escalating doses of ex vivo expanded autologous natural killer (NK) cells in patients with advanced malignancies following bortezomib treatment to sensitize to NK-TRAIL cytotoxicity. Blood. 2010;116:4296, ASH Annual Meeting Abstracts.
38. Lundqvist A, Berg M, Smith A, et al. Bortezomib treatment to potentiate the anti-tumor immunity of ex-vivo expanded adoptively infused autologous natural killer cells. J Cancer. 2011;2:383-385.
39. Miller JS, Soignier Y, Panoskaltsis-Mortari A, et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood. 2005;105: 3051-3057.
40. Cooley S, Foley B, Verneris MR, et al. Haploidentical natural killer (NK) cells expanding in vivo after adoptive transfer exhibit hyperfunction that partially overcomes self tolerance and leads to clearance of refractory leukemia. Blood. 2011;118: 355, ASH Annual Meeting Abstracts.
41. Wilson EB, El-Jawhari JJ, Neilson AL, et al. Human tumour immune evasion via TGF-b blocks nk cell activation but not survival allowing therapeutic restoration of anti-tumour activity. PLoS One. 2011;6:e22842.
42. Szmania S, Greenway A, Lingo J, et al. Impact of elotuzumab therapy on circulating and ex vivo activated/expanded autologous natural killer (auto-ENK) cell activity. Blood. 2013;122:5389, ASH Annual Meeting Abstracts.
43. Collins SM, Bakan CE, Swartzel GD, et al. Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC. Cancer Immunol Immunother. 2013;62: 1841-1849.
44. Benson DM Jr, Bakan CE, Zhang S, et al. IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect. Blood. 2011;118:6387-6391.
45. Kohrt HE, Thielens A, Marabelle A, et al. Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. Blood. 2014;123:678-686.
46. Chan WK, Kung Sutherland M, Li Y, et al. Antibodydependent cell-mediated cytotoxicity overcomes NK cell resistance in MLL-rearranged leukemia expressing inhibitory KIR ligands but not activating ligands. Clin Cancer Res. 2012; 18:6296-6305.
47. Chu J, Deng Y, Benson DM, et al. CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma. Leukemia. 2014;28:917-927.